{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:42:39Z","timestamp":1793241759469,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuro Oncol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1093\/neuonc\/nov300","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T01:23:55Z","timestamp":1453771435000},"page":"991-1001","source":"Crossref","is-referenced-by-count":48,"title":["Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy"],"prefix":"10.1093","volume":"18","author":[{"given":"Frank","family":"Saran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier L.","family":"Chinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,1,24]]},"reference":[{"key":"2016062407583358000_18.7.991.1","unstructured":"Avastin Periodic Safety Update Report (PSUR) (Data on file)."},{"key":"2016062407583358000_18.7.991.2","unstructured":"Avastin\u00ae SPC. Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000582\/WC500029271.pdf . Accessed April 16, 2015."},{"key":"2016062407583358000_18.7.991.3","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0000000000000486"},{"key":"2016062407583358000_18.7.991.4","doi-asserted-by":"publisher","DOI":"10.3171\/2012.9.JNS1277"},{"key":"2016062407583358000_18.7.991.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.08.030"},{"key":"2016062407583358000_18.7.991.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"2016062407583358000_18.7.991.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70025-7"},{"key":"2016062407583358000_18.7.991.8","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.98"},{"key":"2016062407583358000_18.7.991.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345"},{"key":"2016062407583358000_18.7.991.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308573"},{"key":"2016062407583358000_18.7.991.11","unstructured":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program. Available at http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf . Accessed April 16, 2015."},{"key":"2016062407583358000_18.7.991.12","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.291"},{"key":"2016062407583358000_18.7.991.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.2729"},{"key":"2016062407583358000_18.7.991.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2440"},{"key":"2016062407583358000_18.7.991.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8721"},{"key":"2016062407583358000_18.7.991.16","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-120"},{"key":"2016062407583358000_18.7.991.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.10.012"},{"key":"2016062407583358000_18.7.991.18","unstructured":"Temodal\u00ae SPC. Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000229\/WC500035621.pdf . Accessed April 13, 2015."},{"key":"2016062407583358000_18.7.991.19","doi-asserted-by":"publisher","DOI":"10.3171\/2012.9.JNS12504"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/18\/7\/991\/17430544\/nov300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:16:36Z","timestamp":1589627796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/nov300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,24]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,6,24]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1093\/neuonc\/nov300"],"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nov300","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,24]]}}}